Elutia vs LENZ Therapeutics
ELUT and LENZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELUT and LENZ compare
LENZ Therapeutics is the larger company, worth 3.6 times as much as Elutia ($130M against $36.3M).
LENZ Therapeutics grew revenue faster over the last twelve months (330% versus 79.4% for Elutia).
Elutia keeps more of each dollar of sales as profit, with a net margin of 321% compared with −587% at LENZ Therapeutics.
LENZ Therapeutics scores higher on the StockData Score (9 against 8 for Elutia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELUT | LENZ |
|---|---|---|
| Size and price | ||
| Market cap | $36.3M | $130M |
| Share price | $0.820 | $4.13 |
| Change, 1 year | 10.8% | −83.8% |
| Change, 5 years | −85.9% | −94.7% |
| Beta (5Y) | 0.25 | 1.08 |
| Employees | 26 | 152 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× (better) | 6.0× |
| P/B | 2.4× | 0.6× (better) |
| FCF yield | −140% | −88.2% (better) |
| Fair value | $1.05 | $7.62 |
| Margin of safety | 21.9% | 45.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 79.4% | 330% (better) |
| Revenue growth, 5Y average | −22.0% | – |
| Profitability | ||
| Gross margin | 57.7% | – |
| Operating margin | −152% (better) | −632% |
| Net margin | 321% (better) | −587% |
| FCF margin | −299% (better) | −533% |
| Return on equity | – | −59.2% |
| Financial health | ||
| Debt / equity | 0.53 (better) | 0.00 |
| Current ratio | 2.63 | 13.55 (better) |
| Altman Z-score | −5.70 | 2.01 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.8% | 110% |
| Held by insiders | 52.0% | 6.7% |
| Insider net buying, 12 months | $212K (better) | −$8.8M |
| Short interest, % of float | 0.16% | 24.1% |
Go deeper
- ELUT stock overview
- ELUT income statement
- ELUT valuation and score
- LENZ stock overview
- LENZ income statement
- LENZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.